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Despite continuing advances in intensive care medicine, severe
sepsis and septic shock are currently among the most common
causes of morbidity and mortality in intensive care. Moreover,
the incidence of severe sepsis and septic shock has increased
with ageing of the population over the past decade [1-3]. The
Surviving Sepsis Campaign advocates early identification and
intervention worldwide to improve overall management of
sepsis and to reduce sepsis-related death [4,5].
Clinical trials conducted over more than half a century aimed
at reducing the high acute morbidity and mortality rates
associated with severe sepsis have shown that recombinant
human activated protein C (rhAPC), or drotrecogin alfa
(activated), is a treatment that reduces the overall mortality
rate in patients with severe sepsis. However, this knowledge
has been slow to spread, in part because of the complexity
and heterogeneity of this condition, but also because rhAPC
treatment is not without risks. Nevertheless, rhAPC is clearly
a life-saving treatment, and the reduction in mortality far
outweighs the risks involved.
As outlined by the US Food and Drug Administration, rhAPC
should be considered for patients with severe sepsis
resulting in multiple organ failure who are at low risk for
bleeding complications and high risk for death, as indicated
by initial Acute Physiology and Chronic Health Evaluation or
other measurement. Determining who to treat with rhAPC
may be the biggest problem facing intensive care physicians.
Since the publication of the positive results from the
PROWESS (Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis) trial, research into
the protein C pathway has expanded significantly and
additional clinical information about the uses of rhAPC and its
specific activity have been reported. In this supplement to
Critical Care, leading experts describe new insights into the
role of the protein C pathway, along with clinical use of
rhAPC and its results.
The supplement begins with an article by Claessens and
Dhainaut [6]. They review the main proposals of the Surviving
Sepsis Campaign and focus on the difficulties in reaching the
correct diagnosis and in providing appropriate treatment to
septic patients at the right time.
The next two articles focus on the protein C pathway and its
clinical relevance. Levi and van der Poll [7] analyze the
various mechanisms of action of rhAPC in sepsis. Given the
central role played by inadequate functioning of the protein C
pathway in the pathogenesis of sepsis, restoring the function
of this pathway in patients with sepsis appears to be a
rational approach; the beneficial effects of rhAPC in
experimental sepsis models and clinical studies seem to
support this. Although the relative importance of the
anticoagulant relative to the inflammation-modulating effects
is unclear, it is tempting to hypothesize that a combined
effect is responsible for the benefits derived from rhAPC.
Recent studies also suggest that rhAPC has direct anti-
inflammatory properties brought about by its binding to
neutrophils and decreasing chemotaxis [8]. In addition, recent
in vitro studies have shown that rhAPC can modulate the
endothelium by binding to various receptors that are
important for endothelial cell integrity [9].
Vangerow and coworkers [10] describe the predictive value
of plasma protein C levels in sepsis. They also describe the
usefulness of this biomarker for identifying those patients with
severe sepsis who are most likely to benefit from rhAPC and
for helping the clinician to measure the response to rhAPC.
This hypothesis is currently being tested in RESPOND
(Research Evaluation Serial Protein C levels in severe sepsis
patients On Drotrecogin alfa [activated]) a worldwide phase II
study.
The supplement concludes with three practical clinical
articles. In the first of these, Laterre [11] reviews all large
clinical trials of rhAPC. Continued safety assessment is
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essential for any newly approved therapy; in the next article,
Fumagalli and Mignini [12] review the safety profile of rhAPC
in all published studies, which altogether include approxi-
mately 8,000 patients. Using a uniform definition of serious
bleeding to analyze the findings of the various studies, they
demonstrate a consistent rate of serious bleeding of 2.4%
but conclude that this adverse effect is outweighed by the
drug’s benefits in patients with severe sepsis who are at high
risk for death. In the final article, Camporota and Wyncoll [13]
define the patients who are most likely to benefit from rhAPC
and describe when to start and how to manage infusion to
ensure effective treatment while minimizing the risk for bleeding.
We hope that this supplement will provide readers with an
up-to-date summary of the protein C pathway from bench to
bedside, along with practical guidelines for the early
identification of the patients who will benefit from rhAPC and
general recommendations for the appropriate use of rhAPC in
severe sepsis.
We thank all of the authors for their valuable contributions
toward clarifying the controversy about the efficacy and use
of rhAPC in critically ill patients with severe sepsis. Given the
advances made in sepsis care and various scientific
questions surrounding the drug, this is an opportune time to
gather additional clinical evidence on the efficacy, safety and
the benefit-to-risk relationship accompanying rhAPC use and
initiate the new, often requested, phase III placebo-controlled
study PROWESS-SHOCK, scheduled to begin in 2008.
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